Biodel's VIAject gets name change

DANBURY, Conn. A specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes has changed the name of its lead product candidate.

Biodel said that the name Linjeta will replace the name of the company's rapid-acting insulin formulation VIAject, which currently is under review by the Food and Drug Administration.

Errol De Souza, Biodel 's president and CEO, stated, "Today's news reflects the continued progress of the Linjeta new drug application through FDA review and is an important milestone in our effort to commercialize this new drug candidate."